Researchers with The Ohio State University Comprehensive Cancer Center—Arthur G. James Cancer Hospital and Richard J. Solove Research Institute are investigating how dietary interventions could help reduce fatigue, improve diet quality and help cancer patients live an overall better quality of life.
Research from UPMC Hillman Cancer Center is challenging the prevailing hypothesis for how donor stem cell grafts cause graft-versus-host disease and offers an alternative model that could guide development of novel therapies.
UT Southwestern Medical Center researchers discovered a method cells use to turn genes on and off that involves portions of proteins whose function has long been a mystery. The findings, reported in Cell, could lead to new ways of controlling gene regulation and may one day lead to new treatments for a broad array of diseases.
Utilizing artificial intelligence along with traditional pathology offers promise for swiftly developing treatment plans for patients with non-small cell lung cancers, a team led by UT Southwestern Medical Center researchers discovered.
Age-based heuristics can lead to large differences in breast cancer treatment based on small differences in chronologic age, according to a new analysis of more than 500,000 patient records.
Although widespread use of immune checkpoint inhibitors in patients with advanced lung cancer has led to meaningful improvements in survival in younger patients, older patients have not experienced similar survival benefits, new research from Yale Cancer Center shows.
Results from the SWOG S1416 clinical trial showed that adding veliparib to chemotherapy can significantly extend progression-free survival times in patients with TNBC that has a “BRCA-like” phenotype.
Data from a Yale Cancer Center-led clinical trial show improved rates of survival and reduced risk of recurrence in patients taking Tagrisso (osimertinib), a targeted therapy for non-small cell lung cancer.
Merck will stop the phase III KEYNOTE-991 trial investigating Keytruda (pembrlizumab), Merck’s anti-PD-1 therapy, in combination with Xtandi (enzalutamide) and androgen deprivation therapy for the treatment of patients with metastatic, hormone-sensitive prostate cancer.
Patients with myelofibrosis had clinically significant improvement in disease-related symptoms, including anemia and spleen enlargement, when treated with the targeted therapy momelotinib, according to results from the international phase III MOMENTUM trial led by researchers at MD Anderson Cancer Center.
